ReviewTranslational andrology and urology2020
Selective androgen receptor modulators: the future of androgen therapy?
Review in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 121 citations in OpenAlex.
- Treatment with a selective androgen receptor modulator (RAD140) is linked to better cardiac function, with male-specific effects that are graded by interleukin-6.GeroScience · 2026Article
- Limitations of Molecular Docking in Predicting the Selectivity of Selective Androgen Receptor Modulators (SARMs): A Comparative Study of YK11 and Ostarine Across Five Nuclear Receptors.International journal of molecular sciences · 2026Article
- Selective Androgen Receptor Modulators in Women: What Do We Know, and What Is Still Missing.Life (Basel, Switzerland) · 2026Review
- Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers.Molecular imaging and biology · 2026Review
- Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- A Computational and In Vitro Appraisal of Ostarine to Target Androgen Receptor in Glioma C6 Cells.Cell biochemistry and biophysics · 2025Article
- Interference with systemic negative feedback as a potential mechanism for nonmonotonic dose-responses of endocrine-disrupting chemicals.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density.Physiological reports · 2025Article
- When Gains Go Wrong: A Case of Selective Androgen Receptor Modulator-Related Liver Injury.Cureus · 2025Article
- Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management.Osteoporosis and sarcopenia · 2025Review
- Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.International journal of molecular sciences · 2025Review
- Selective androgen receptor modulators: a critical appraisal.Frontiers in endocrinology · 2025Review
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.BMC medicine · 2024Review
- Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use.JCEM case reports · 2024Article
- Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.Journal of clinical medicine · 2024Review
- RISING STARS: Androgens and immune cell function.The Journal of endocrinology · 2024Review
- Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers.Sexual medicine · 2024Article
- Advantage of ostarine over raloxifene and their combined treatments for muscle of estrogen-deficient rats.Journal of endocrinological investigation · 2024Article
- Sarcopenia as the Mobility Phenotype of Aging: Clinical Implications.Journal of bone metabolism · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional androgen therapy. SARMs have few side effects and excellent oral and transdermal bioavailability and may, therefore, represent viable alternatives to current androgen therapies. SARMs have been studied as possible therapies for many conditions, including osteoporosis, Alzheimer's disease, breast cancer, stress urinary incontinence (SUI), prostate cancer (PCa), benign prostatic hyperplasia (BPH), male contraception, hypogonadism, Duchenne muscular dystrophy (DMD), and sarcopenia/muscle wasting/cancer cachexia. While there are no indications for SARMs currently approved by the Food and Drug Administration (FDA), many potential applications are still being explored, and results are promising. In this review, we examine the literature assessing the use of SARMS for a number of indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.